AI-Designed Antibody Sequences
Backed by Independent Lab Validation
Securely in Your Inbox in 2 Weeks
Any research purpose. Any protein target.
Receive human antibody sequences.
Screened for affinity & developability.
Ready for synthesis.
How It Works
1. Select your target, epitope, and format
Choose the target, epitope (if known), and preferred format (VHH or VH/VL) to define the antibody search space for computational screening.
2. Select your purchase tier
Choose your tier that fits your research based on the number of sequences, iteration rounds, sequence exclusivity, and budget.
3. AI generated
Human reviewed
Your sequences are generated using HyperBind and reviewed by EVQLV scientists to ensure the highest quality antibodies.
4. Receive your sequences
Receive your synthesis-ready antibody sequences securely delivered to your inbox. Here is an example of what you'll receive.
Abtique is Built for Scientists Who Move Science Forward
For scientists and discovery leaders who need to advance antibody programs with rigor, transparency, and speed.
Abtique provides scientists, R&D leaders, and innovators with ready-to-test, fully human antibody sequences, generated through validated computational screening with direct human oversight, ensuring every sequence meets our rigorous standards. No long-term contracts. No new infrastructure. Just transparent results, delivered in weeks.
Try Verified AI Antibody Design — Without the Overhead
Experience a validated antibody-design workflow. No setup, no long contracts. Select your target and tier to receive synthesis-ready human antibody sequences in as little as 2 weeks.
Our Science
Abtique is powered by HyperBind, an antibody design platform built on a fundamentally different approach: iterative lab-to-AI refinement that improves with every experimental round. Unlike platforms that can't learn from limited lab data, HyperBind adapts to your specific experimental system with each screening round, learning from what doesn't bind, not just what does.
In an independent validation study conducted by a partner lab, HyperBind generated 23 high-affinity antibodies (KD ≤ 100 nM) against a challenging GPCR target, including 3 candidates below 10 nM—demonstrating that computational design guided by experimental feedback can achieve binding strengths comparable to therapeutic-grade antibodies.
Across a wide range of targets—from peptidases to neuronal proteins—partner labs have independently reproduced these outcomes using their own experimental criteria and success thresholds.
— Read the data and validation behind HyperBindWorks with your existing workflow: Integrates data from display, SPR, BLI, or ELISA and learns from panels containing as few as 10 measurements.
Learns from screening failures: Extracts predictive signal from every measurement, including lab negatives, so fewer experiments are needed.
Lab-to-AI feedback loop: Sequential refinement improves prediction accuracy to your target's unique binding properties.
What You'll Receive
Every project includes comprehensive sequence data with detailed annotations, CDR regions, germline assignments, and full amino acid sequences—ready for synthesis and testing.
Heavy Chains
Complete heavy chain sequences with CDR annotations, germline identity, and position-by-position amino acid data.
View Example →Light Chains
Complete light chain sequences (kappa/lambda) with CDR annotations, germline identity, and position-by-position amino acid data.
View Example →Example data shown for reference. Your actual deliverables will contain sequences specific to your target protein.
One-time project pricing. No milestones. No royalties. No subscriptions.
Transparent project-based pricing for every stage of discovery.
Discovery
$9,600
Designed for early exploration For small-scale or early discovery projects
- 24 target-specific sequences, developability-optimized
- Single discovery round for rapid feasibility testing
- Diversity across CDRs for targeted insight
- Non-exclusive sequences
Exclusive
$48,600
Validated multi-round refinement For scientists advancing iterative discovery and sequence protection
- 288 target-specific sequences (over 3 rounds)
- Three feedback-informed rounds of 96 sequences
- HyperBind-guided refinement between each round
- Broadest diversity across CDRs to explore full candidate space
- EXCLUSIVITY on the project sequences we deliver
- Validated in published results demonstrating multi-round refinement
Compare Your Options
No paperwork. No sales calls.
Just transparent, scalable antibody design.
Validated methods. Transparent results.
Ready when you are.
Direct feedback from scientists using EVQLV for antibody discovery and engineering
I've been working in protein design for more than 20 years, and this is one of the most remarkable examples of antibody-to-target design I've seen in my career.
Director of the Institute of Research and Innovation Parc Taulí
More than half of the sequences you sent us bound higher than the gold standard and were specific to the target. We are excited to continue working on them.
If we had used your technology earlier, instead of in vitro methods, we would have saved more than a year on this project and would be closer to the clinic.
We've never moved this fast on a GPCR. The efficiency really surprised us.
I've been working in protein design for more than 20 years, and this is one of the most remarkable examples of antibody-to-target design I've seen in my career.
Director of the Institute of Research and Innovation Parc Taulí
All the sequences expressed on the first pass, and we're looking forward to testing them.
We compared four AI tools. Yours was the only one that produced validated hits.
We tried you because it was fast and low-risk. We'll keep using you because the sequences worked.
HYPERBIND SEQUENCES HAVE SUPPORTED RESEARCH AT
